Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
---|---|---|---|---|---|
Johnson & Johnson | 10%+ Owner | $33.7M | Apr 9, 2024 | ||
Versant Venture Capital VI, L.P. | 10%+ Owner | $8.93M | Apr 9, 2024 | ||
Daniel S. Lorrain | Chief Scientific Officer | $2.76M | -$118K | -4.08% | Jan 31, 2025 |
Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | $218K | Jan 31, 2025 | ||
Carmine N. Stengone | CEO and President, Director | $198K | Jan 31, 2025 | ||
Olivia C. Ware | Director | May 24, 2024 | |||
Troy Ignelzi | Director | May 24, 2024 | |||
John Stephen Healy | General Counsel and Corp Sec | Jan 31, 2025 | |||
Sarah Boyce | Director | Jun 24, 2024 | |||
Peter Slover | Chief Financial Officer | Jan 31, 2025 | |||
Todd R. Brady | Director | May 24, 2024 | |||
Lori Lyons-Williams | Director | May 24, 2024 | |||
Evert B. Schimmelpennink | Director | May 24, 2024 |
Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
---|